Document is current
Any future updates will be listed below
-
Authors
Mercer-Smith, Alison R.
Buckley, Andrew
Valdivia, Alain
Jiang, Wulin
Thang, Morrent
Bell, Noah
Kumar, Rashmi J.
Bomba, Hunter N.
Woodell, Alex S.
Luo, Jie
Floyd, Scott R.
Hingtgen, Shawn D. https://orcid.org/0000-0003-4355-2377
-
Funding
Funding for this research was provided by:
Eshelman Institute for Innovation, University of North Carolina at Chapel Hill (Eshelman Institute for Innovation, University of North Carolina at Chapel Hill)
National Cancer Institute (F30CA243270)
American Cancer Society (RSG-19-030-01-DMC)
- License Information
-
More Information
Article History
Accepted: 10 April 2022
First Online: 19 April 2022
Declarations
:
: SDH has an ownership interest in Falcon Therapeutics, Inc., which has licensed aspects of hiNSC technology from the University of North Carolina at Chapel Hill. ARM, WJ, AV, AB, MT, NB, and SRF have no conflicts to disclose.
: All experimental mouse protocols were previously approved by the Institutional Animal Care and Use Committees at University of North Carolina -- Chapel Hill.
: Not applicable.
: Not applicable.
